- Case Report
- Open Access
Advanced gastric cancer showing long-term complete remission in response to S-1 monotherapy: two case reports
© Mitomi et al; licensee BioMed Central Ltd. 2008
- Received: 03 September 2008
- Accepted: 18 December 2008
- Published: 18 December 2008
We herein report two cases showing long-term complete remission (CR) in response to S-1 monotherapy. Case 1 was a 65-year-old male diagnosed with an advanced poorly differentiated adenocarcinoma of the stomach with paraaortic lymph node metastases, which disappeared after S-1 monotherapy. Subsequently a total gastrectomy was performed, and histological CR was evident. His progress is presently uneventful without recurrence 50 months after surgery. Case 2 was a 59-year-old female who underwent a total gastrectomy with a jejunal pouch. The resected tumor was a medullary type poorly differentiated adenocarcinoma infiltrating the serosa and involving the regional lymph nodes. One year after surgery, endoscopy revealed a recurrent tumor in the jejunal pouch. After the administration of S-1, this recurrent tumor completely disappeared, and she has since maintained CR for 39 months. These cases suggest that a subgroup of patients with advanced gastric cancer may attain CR with S-1 monotherapy.
- Gastric Cancer
- Complete Remission
- Advanced Gastric Cancer
- Total Gastrectomy
- Metastatic Gastric Cancer
S-1 is an oral antitumor agent that exploits the biochemical modulation of 5-fluorouracil (FU) pharmacokinetics. S-1 contains tegafur, gemistat and otastat potassium. Gemistat inhibits 5-FU degradation and maintains prolonged 5-FU concentrations. Otastat potassium alleviates the gastrointestinal toxicity induced in the host by 5-FU. In phase II studies, S-1 has demonstrated high response rate for advanced gastric cancers without serious adverse reactions.[2, 3] However, complete responses (CRs) with long-term survival are rare.[2, 4, 5] We report herein two cases of advanced gastric cancer showing long-term CR after S-1 monotherapy.
This report documents two cases of advanced (stage IV) gastric cancer showing long-term CR to S-1 monotherapy; In case 1, CR was histologically verified in the surgically resected stomach, and in case 2 this was presented for a suture line recurrence in the jejunal pouch.
In phase II studies of S-1 in patients with advanced gastric cancer, the overall response rate has been approximately 40–50%.[2, 3] A retrospective analysis of single-agent chemotherapy of S-1 for patients with advanced gastric cancer revealed it to be modestly effective with a 26–38% in response rate.[4, 5] However, CR was rare with an incidence of only 2–4%[2, 4, 5] and histological verification in surgically resected stomachs was extremely rare. Mori et al. reported a patient with histological CR after a 2-week regimen of S-1 as single-agent chemotherapy for an advanced cancer. In that case; the biopsy specimen featured a signet-ring cell type of poorly differentiated adenocarcinoma. The response rate for poorly differentiated (diffuse type) adenocarcinomas is reported to be higher than for well differentiated (intestinal type) lesions. S-1 is also effective against the two present cases diagnosed as medullary subtype of poorly differentiated histology.
Few reports have documented advanced gastric cancer with long-term remission after neoadjuvant chemotherapy with S-1 alone; two patients with advanced or metastatic gastric cancer, who responded to S-1 monotherapy and demonstrated clinical CR for about 4 years.[8, 9] In another report, a very short course of S-1 alone achieved long-term CR of metastatic gastric cancer. Curative surgery following downstaging with S-1 monotherapy has also been successfully performed for metastatic disease patients with long-term CR after surgery.
Kimura et al. devised an alternative dosing regimen for S-1, i.e. 2-week regimen, and conducted a retrospective study to evaluate the efficacy and feasibility of this schedule in comparison with the 4-week regimen. In their study, the incidence of adverse reactions tend to be lower in the 2-week regimen group (77%) than in the 4-week group (93%), with response rates of 23% and 21%, respectively. In the present case 1, the standard 4-week regimen was well tolerated, and in case 2, the 2-week regimen was more feasible because of toxicity at the standard dose; both cases fortunately showed long-term CR.
Jejunal pouch recurrence after gastrectomy for gastric cancer has rarely been described.[13, 14] Interestingly, the earlier tumors, like the current case, were medullary type poorly differentiated adenocarcinomas characterized by a location in the upper part of the stomach, grossly expansive growth, frequently vascular permeation, and simultaneous liver metastasis, but not jejunal pouch recurrence. The cause of pouch recurrence is speculated that exfoliated cancer cells were intraluminally implanted at the jejunal mucosa, or extraluminally transplanted by the stapling device. Alternatively, our speculation of the cause is lymphatic theory because of the fact that the tumor of the present case 2 had extensive lymph node metastasis.
In conclusion, the two documented cases of advanced gastric cancer showed long-term CR in response to S-1 monotherapy. At present, a standard neoadjuvant strategy for advanced gastric cancer has not been established, but oral intake S-1, which is desirable in the outpatient setting because of its feasibility and mild toxicity, might prove to be considered as a possible alternative chemotherapeutic regimen for such patients, but we definitely need large randomized controlled trial.
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
The costs of publication of this article were defrayed in part by Taiho Pharmaceutical Co., Ltd. (Tokyo, Japan). We thank Y. Oya, J. Kubo, M. Numata and N. Anpo, Pathology Division, National Hospital Organization Sagamihara Hospital, for their expert technical assistance.
- Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anti-Cancer Drugs. 1996, 7: 548-57. 10.1097/00001813-199607000-00010.View ArticlePubMedGoogle Scholar
- Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer. 1998, 34: 1715-20. 10.1016/S0959-8049(98)00211-1.View ArticlePubMedGoogle Scholar
- Koizumi W, Kurihara M, Nakano S, Hasegawa K: The S-1 Cooperative Gastric Cancer Study Group. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology. 2000, 58: 191-7. 10.1159/000012099.View ArticlePubMedGoogle Scholar
- Yonemori K, Shimada Y, Goto A, Ura T, Arai T, Hamaguchi T, Muro K, Yamada Y, Shirao K: Retrospective analysis of clinical results and predictors of response in chemo-naïve patients with advanced gastric cancer treated with S-1, an oral fluoropyrimidine derivative, as single-agent chemotherapy. Gastric Cancer. 2004, 7: 204-10. 10.1007/s10120-004-0294-3.View ArticlePubMedGoogle Scholar
- Kawai H, Ohtsu A, Boku N, Hamamoto Y, Nagashima F, Muto M, Sano Y, Mera K, Yano T, Doi T, Yoshida S: Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey. Gastric Cancer. 2003, 6: 19-23. 10.1007/s10120-003-0216-9.View ArticlePubMedGoogle Scholar
- Japanese Gastric Cancer Association: Japanese classification of gastric carcinoma. 2 nd English ed. Gastric Cancer. 1998, 1: 10-24. 10.1007/PL00011681.View ArticlePubMedGoogle Scholar
- Mori S, Kishimoto H, Tauchi K, Higuchi K: Histological complete response in advanced gastric cancer after 2 weeks of S-1 administration as neoadjuvant chemotherapy. Gastric Cancer. 2006, 9: 136-9. 10.1007/s10120-005-0358-z.View ArticlePubMedGoogle Scholar
- Suzuki Y, Kawasaki N, Ishibashi Y, Takahashi N, Kashiwagi H, Koba K, Urashima M, Yanaga K: A case of stage IV gastric cancer: long-term remission achieved with S-1 monotherapy. JMAJ. 2006, 49: 219-23.Google Scholar
- Ueda Y, Yamagishi H, Yamashita T, Itoh N, Itoi H, Shirasaka T, Ajani JA: S-1-induced, prolonged complete regression of lung metastasis from gastric cancer refractory to 5'-DFUR: a case report with pharmacokinetic study. Jpn J Clin Oncol. 2004, 34: 282-6. 10.1093/jjco/hyh044.View ArticlePubMedGoogle Scholar
- Schöffski P, Chollet P, Ganser A, Wiese K-H, Rambusch E, deVries MJ, Hanauske A: EORTC Early Clinical Studies Group. Complete response of a gastric primary after a short but toxic course of 'S-1. Ann Oncol. 1999, 10: 1117-20. 10.1023/A:1008364601010.View ArticlePubMedGoogle Scholar
- Iwazawa T, Kinuta M, Yano H, Matsui S, Tamagaki S, Yasue A, Okada K, Kanoh T, Tono T, Nakano Y, Okamoto S, Monden T: An oral anticancer drug, TS-1, enabled a patient with advanced gastric cancer with Virchow's metastasis to receive curative resection. Gastric Cancer. 2002, 5: 96-101. 10.1007/s101200200016.View ArticlePubMedGoogle Scholar
- Kimura Y, Kikkawa N, Iijima S, Kato T, Naoi Y, Hayashi T, Tanigawa T, Yamamoto H, Kurokawa E: A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice. Gastric Cancer. 2003, 6: 34-9. 10.1007/s10120-003-0230-y.View ArticlePubMedGoogle Scholar
- Miyoshi K, Fuchimoto S, Ohsaki T, Sakata T, Takeda I, Takahashi K, Ohkawa T, Tanaka K, Matsumoto T, Takakura N, Motoi M: Suture line recurrence in jejunal pouch replaced after gastrectomy for gastric cancer. Gastric Cancer. 1999, 2: 194-7. 10.1007/s101200050046.View ArticlePubMedGoogle Scholar
- Nishimura M, Honda I, Watanabe S, Nagata M, Souda H, Miyazaki M: Recurrence in jejunal pouch after proximal gastrectomy for early upper gastric cancer. Gastric Cancer. 2003, 6: 197-201. 10.1007/s10120-003-0242-7.View ArticlePubMedGoogle Scholar
- Adachi Y, Mori M, Maehara Y, Sugimachi K: Poorly differentiated medullary carcinoma of the stomach. Cancer. 1992, 70: 1462-6. 10.1002/1097-0142(19920915)70:6<1462::AID-CNCR2820700603>3.0.CO;2-E.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.